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Abstract
Background: It is a daunting task to identify all the metabolic pathways of brain energy metabolism and
develop a dynamic simulation environment that will cover a time scale ranging from seconds to hours. To
simplify this task and make it more practicable, we undertook stoichiometric modeling of brain energy
metabolism with the major aim of including the main interacting pathways in and between astrocytes and
neurons.
Model: The constructed model includes central metabolism (glycolysis, pentose phosphate pathway, TCA
cycle), lipid metabolism, reactive oxygen species (ROS) detoxification, amino acid metabolism (synthesis
and catabolism), the well-known glutamate-glutamine cycle, other coupling reactions between astrocytes
and neurons, and neurotransmitter metabolism. This is, to our knowledge, the most comprehensive
attempt at stoichiometric modeling of brain metabolism to date in terms of its coverage of a wide range
of metabolic pathways. We then attempted to model the basal physiological behaviour and hypoxic
behaviour of the brain cells where astrocytes and neurons are tightly coupled.
Results: The reconstructed stoichiometric reaction model included 217 reactions (184 internal, 33
exchange) and 216 metabolites (183 internal, 33 external) distributed in and between astrocytes and
neurons. Flux balance analysis (FBA) techniques were applied to the reconstructed model to elucidate the
underlying cellular principles of neuron-astrocyte coupling. Simulation of resting conditions under the
constraints of maximization of glutamate/glutamine/GABA cycle fluxes between the two cell types with
subsequent minimization of Euclidean norm of fluxes resulted in a flux distribution in accordance with
literature-based findings. As a further validation of our model, the effect of oxygen deprivation (hypoxia)
on fluxes was simulated using an FBA-derivative approach, known as minimization of metabolic adjustment
(MOMA). The results show the power of the constructed model to simulate disease behaviour on the flux
level, and its potential to analyze cellular metabolic behaviour in silico.
Conclusion: The predictive power of the constructed model for the key flux distributions, especially
central carbon metabolism and glutamate-glutamine cycle fluxes, and its application to hypoxia is
promising. The resultant acceptable predictions strengthen the power of such stoichiometric models in
the analysis of mammalian cell metabolism.
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Background
Understanding of the biochemistry and energy metabo-
lism of the brain is a prerequisite for evaluating the func-
tioning of the central nervous system (CNS) as well as the
physiology and pathology of the brain. The functions of
the CNS are mainly excitation and conduction as reflected
in the continuous electrical activity of the brain. The fact
that this electrical energy is ultimately derived from chem-
ical processes reveals the fundamental role of biochemis-
try in the operation of the brain.
Developments in functional brain imaging techniques
have led to better elucidation of the physiological and
biochemical mechanisms of the brain [1-4]. However, the
exact mechanism still remains unknown. To simplify and
interpret the actual metabolic mechanisms, mathematical
models are commonly used as techniques to supplement
the available experimental studies [5-9] where biochemi-
cal equations are solved in a systematic way to explain the
missing physiological responses.
Brain energy metabolism has been approached by the use
of dynamic modeling [5,8] where the main interaction
takes place between the neuron and the blood stream. On
the other hand, brain function depends on the coordi-
nated activities of a multitude of cell types, such as neu-
rons, astrocytes and microglia. Astrocytes play an
important role in maintaining brain metabolism which,
when disturbed, might lead to neurological diseases
[10,11]. These two types of cells (i.e. neurons and astro-
cytes) are also important in neurotransmitter metabolism
[12-14]. It was experimentally shown [1,10,11] that the
interactions between neurons and their neighboring
astrocytes required more thorough investigation [15-17]
for a better understanding of the neurovascular and neu-
rometabolic coupling specifically in pathological condi-
tions. To date, it has proved a daunting task to identify all
the metabolic pathways of brain energy metabolism and
develop a dynamic simulation environment that will
cover a time scale ranging from seconds to minutes to
hours. To simplify this task and to make it more practica-
ble, we undertook stoichiometric modeling of brain
energy metabolism with the major aim of including all
the known pathways between astrocytes and neurons.
We performed an extensive literature survey to obtain the
catabolic, anabolic and exchange reactions in brain
metabolism. Only about 100 references cited directly
within the text are listed here. The ultimate goal was to
develop a reliable stoichiometric model of the coupling
mechanism, which will be compatible with physiological
observations. The constructed model included central
metabolism (glycolysis, pentose phosphate pathway, TCA
cycle), amino acid metabolism (synthesis and catabo-
lism), lipid metabolism, ROS detoxification pathway,
neurotransmitter metabolism (dopamine, acetylcholine,
norepinephrine, epinephrine, serotonine) as well as cou-
pling reactions between astrocytes and neurons. The met-
abolic reactions were compartmentalized with respect to
their localization in cells (astrocyte, neuron) to obtain a
more realistic representation. Additionally, cofactor
(NADH, NADPH, FADH2) localization in cytosol or mito-
chondria was reflected in the compiled reaction list. This
is, to our knowledge, the first comprehensive attempt at
stoichiometric modeling of brain metabolism in terms of
its coverage of a wide range of metabolic pathways (214
reactions). Flux balance analysis (FBA), a steady-state met-
abolic modeling technique [18,19], was applied to the
reconstructed model to seek answers to the following
questions: i) how the available fuel is shared among dif-
ferent pathways of the brain, ii) which quantifiable astro-
cyte-neuron interactions can be identified under resting
conditions, iii) whether the neurotransmitters are pro-
duced at maximal rate in these conditions, and iv)
whether hypoxia, a very common causative factor associ-
ated with neurological diseases, can be explained by the
stoichiometric modeling of neuron-astrocyte coupling.
The constructed model was also used to identify the inter-
mediary biochemical reactions and elements that partici-
pate in trafficking (eg. glutamate-glutamine, branched-
chain amino acid shuttles) and to examine the interac-
tions among the pathways. The predictions were verified
by comparing corresponding flux distributions to litera-
ture findings from a pathway-oriented perspective.
Results and Discussion
Metabolic model reconstruction
The main interaction site of neurons and astrocytes is
known to be the synaptic cleft. Since both neurons and
astrocytes require proximity to blood vessels for transmis-
sion of metabolites, a representation of this cellular
organization is reconstructed (Figure 1). Although these
interactions are known to occur in various time scales, the
model assumes steady-state in metabolic pathways and
guides us to investigate normal versus abnormal condi-
tions of brain energy metabolism. Hence, we tried to
incorporate as many of the pathways as possible into the
model.
A previous attempt for stoichiometric modeling of brain
metabolism [6] covered 16 reactions that mainly occur
among glutamate and TCA cycle intermediates. That
model was used to simulate the conditions where the
glutamate-glutamine cycle was inactive. The present
reconstruction, on the other hand, is an attempt to model
the basal physiological behaviour of brain cells, where the
cycle is known to be active, through tight coupling
between astrocytes and neurons. Our reconstructed
model therefore includes the well-known glutamate-
glutamine cycle, as well as other metabolic couplings andTheoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
Page 3 of 18
(page number not for citation purposes)
neurotransmitter synthesis reactions for the first time in
the literature. Hence, this is the most comprehensive stoi-
chiometric brain model developed to date. The con-
structed stoichiometric model consists of 217 reactions
(184 internal, 33 exchange) and 216 metabolites (183
internal, 33 external) distributed in and between astro-
cytes and neurons (Additional File 1). Seventy-eight of the
internal reactions occur in astrocytes, and 90 of them are
localized in neurons. A high percentage co-occur in both
cell types. The fact that the remaining 16 reactions are
intercompartmental indicates the coverage of neuron-
astrocyte coupling mechanisms by the constructed model.
Additional File 2: Supplementary Table 1 details the met-
abolic differences in the two cell types reflected in the
model reactions. Thirty-one of the 216 metabolites are
taken as extracellular since they are associated with either
an uptake (glucoseA,N, oxygenA,N, ammoniaA, leucineA,
isoleucineA, valineA, phenylalanineN, tryptophanN,
lysineN, tyrosineN, linoleateA,N, linolenateA,N, cholineA,N,
cystineA) or a release (CO2
A,N, lactateA, dopamineN, acetyl-
cholineN, norepinephrineN,A, epinephrineN, melatoninN,
serotoninN, glutamineA, glutathioneN) mechanism. Addi-
tionally, synthesized lipids in both cell types were consid-
ered as released for the modeling purposes.
As proposed [20-23], the main energetic pathways of
brain (glycolysis, PP pathway, TCA cycle and oxidative
phosphorylation) were considered to occur in both cell
types (r1–r37/r38–r73), except the pyruvate carboxyla-
tion reaction (r12), whose enzyme is known to be inactive
in neurons [17,24]. That is why neurons cannot replenish
their TCA cycle intermediates and their derivatives,
Metabolic interactions between astrocytes and neurons with major reactions Figure 1
Metabolic interactions between astrocytes and neurons with major reactions. Thick arrows show uptake and 
release reactions. Dashed arrows indicate shuttle of metabolites between two cell types. Glutamate and α-ketoglutarate in 
transamination reactions are abbreviated as GLU and AKG, respectively. All reactions considered in the modeling are given in 
additional file 1. The reaction numbers in the figure refer to the numbering in the reaction list of additional file 1. Here we only 
depict major reactions for simplicity.
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including glutamate, from glucose on their own. Since
cofactors cannot cross the mitochondrial membrane, their
localization was reflected in the reactions. Accordingly,
pyruvate dehydrogenation (r13, r49), is mitochondrial.
Both NADH-(mitochondrial) and NADPH-dependent
(mitochondrial and cytosolic) isocitrate dehydrogenation
reactions (r24–r26/r60–r62) were taken into account
[25]. Malic enzyme is confined to the cytosol in astrocytes
(r33) whereas it is only mitochondrial in neurons (r69)
[26-28]. The malate-aspartate shuttle plays an important
role in neurons, by transferring reducing equivalents
(NADH) from the cytosol to mitochondria for ATP syn-
thesis through oxidative phosphorylation [29-33].
Accordingly, a cytosolic version of malate dehydrogena-
tion (r69) in the reverse direction was included in neu-
rons in addition to the mitochondrial version, to mimick
the shuttle. In astrocytes, however, cytosolic malate dehy-
drogenation was considered in the same direction as the
mitochondrial one since it is known that the malate-
aspartate shuttle is not active in astrocytes [29,31],
although cytosolic malate dehydrogenase is present in
this cell type [34,35]. The mitochondrial transhydroge-
nase converting NADH to NADPH [36] was also consid-
ered. ATP consumption by the ATPase pumps and other
processes (r37/r73) was also accounted for. Lactate release
was assumed to be only from the astrocytes [37] since it is
known that neuron metabolism is primarily oxidative.
An extensive literature survey was performed to acquire
the compartmentation of amino acid catabolism and syn-
thesis between astrocytes and neurons. For the glutamate
– glutamine cycle (r74–r79) [38,39], glutamate is released
from neurons and subsequently taken up by astrocytes
and returned to neurons via synaptic clefts again in the
form of glutamine. Unlike astrocytes, neurons cannot
generate glutamine from glutamate owing to the lack of
the glutamine synthetase enzyme [13]. They have glutam-
inase enzyme instead (r79) to convert astrocyte-derived
glutamine into glutamate. One alternative for neuronal
glutamate production is the transfer of TCA cycle interme-
diates from astrocytes to neurons. However, these
exchange reactions were not added to the model since
there is not sufficient evidence for such trafficking
[13,16,40,41]. Since glutamate uptake by astrocytes acti-
vates Na+K+ATPase [42,43], the associated consumption
of 1 ATP was included in the corresponding equation
(r75). Glutamine efflux from the astrocytes to the extracel-
lular space [7,44] was taken into account as well. Gluta-
mate dehydrogenase is located in mitochondria, and this
is reflected in the cofactor specification of the correspond-
ing reactions (r74, r76) [45].
NMR studies indicate that the GABA, aspartate and
alanine pathways are closely linked to the glutamate –
glutamine cycle [40,46]. GABA is assumed to be formed
by the decarboxylation of glutamate (r80) in neurons and
then transferred into the neighboring glial cells where it is
converted into glutamate and succinate irreversibly
(r81–r83) [47,48]. Conversion to succinate is also possible
in neurons (r84–r85) [49]. Aspartate can be formed both in
astrocytes and neurons reversibly via transamination (r86,
r88), and it can be transferred between the two cell types in
both directions (r87) [40,47]. It has been claimed [50,51]
that alanine is released by neurons, taken up by astrocytes
and transformed into pyruvate and acts as a nitrogen car-
rier from neurons to astrocytes. On the other hand, it has
been suggested [52] that alanine is produced and released
by astrocytes for the use of neurons. To consider both pos-
sibilities, these reactions and transfer of alanine between
the cell types were defined as reversible (r89–r91).
Serine and glycine are involved in a cycle between astro-
cytes and neurons analogous to the glutamate-glutamine
cycle [53,54]. There is no 3-phosphoglycerate dehydroge-
nase activity in neurons; hence the corresponding reaction
only occurs in astrocytes [55]. The cofactor localization of
the reaction (r92) is cytosolic [56]. Once formed from
glutamate and 3-phosphoglycerate in astrocytes (r92) [55-
57], serine can be transported to neurons (r94), where it is
converted to glycine (r95) [48,58]. Conversion of serine to
pyruvate (r93) is also possible in astrocytes [53,58,59].
Neuronal glycine can be transported to astrocytes (r96)
[48], where it is converted back to serine (r98), completing
the cycle [54,58,60]. Additionally, the glycine cleavage
system (r97) is exclusively active in astrocytes [54,61], and
located in mitochondria.
Inclusion of branched chain amino acids (BCAA) in the
model is crucial for the investigation of brain metabolism
coupling and the glutamate – glutamine cycle because
they serve as nitrogen donors for glutamate and transfer
nitrogen from astrocytes to neurons [62-64]. BCAA
metabolism is compartmented between astrocytes and
neurons. Astrocytes take up leucine from the blood brain
barrier [65] and oxidize it so as to form a branched chain
keto acid, α-ketoisocaproate (KIC) (r99), to supply amino
nitrogen to the glial glutamate pool. Then KIC is trans-
ferred into the neuronal compartment (r104) and con-
verted back to leucine (r105). The cycle is finalized by the
conveyance of leucine to the astrocyte (r106) [64,66]. It is
also possible that leucine in the form of KIC enters the
astrocytic TCA cycle as acetyl-CoA [64], as considered by
the model (r100–r103). The other branched chain amino
acids, valine and isoleucine, are associated with compara-
bly lower uptake rates [67]. Their mechanisms in brain are
essentially similar, except the last step where they are con-
verted not to acetoacetyl-CoA but to succinyl-CoA
(r107–r119) [64,68]. Branched chain keto acid dehydroge-
nase reactions (r100, r108, r115) take place in mitochondriaTheoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
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[26,69,70], together with branched chain acyl-coa dehy-
drogenase reactions (r101, r109, r116) [26,68,71].
Lysine catabolism via the saccharopine pathway has been
shown to occur mostly in neurons [72]. Hence, lysine was
allowed to be taken up by neurons leading to glutamate
production (r120–r121) and it was degraded to acetyl-CoA
(r122–r124) [68,72]. The pathway is cytosolic until the for-
mation of alpha-ketoadipate (r121), after which it takes
place in mitochondria (r123) [68]. No astrocytic pathway
was considered for lysine since there was no suggested
mechanism for this cell type in the literature.
Phenylalanine taken up from the extracellular space is cat-
abolized to tyrosine (r125) [48,73,74]. Tyrosine, coming
from phenylalanine or transported from the blood, is con-
verted to DOPA by tyrosine hydroxylase using oxygen in
neurons, and this is eventually converted into the neuro-
transmitter dopamine (r126–r127) [48,75-77]. As the neu-
rotransmitters are synthesized in neurons, uptake of the
corresponding substrate, tyrosine, from the blood-brain
barrier was assumed neuronal. This can be followed by
norepinephrine and epinephrine syntheses (r128–r129).
Dopamine can be released from neurons into the synaptic
cleft or stored in vesicles [76]. Therefore, dopamine
release to extracellular space was included in the model.
Moreover, it has been reported that dopamine is taken up
by astrocytes from the synaptic cleft and converted to
norepinephrine [78]. This suggested metabolite traffick-
ing was also taken into account in the model (r130–r131).
Tryptophan serves as a precursor for the synthesis of sero-
tonin and melatonin in neurons following its uptake
(r132–r134) [79]. Since serotonin is stored in vesicles, it is
considered as extracellular. Acetylcholine as a neurotrans-
mitter is synthesized from acetyl-CoA in neurons (r135)
[48].
Although they are essential amino acids for brain, the
catabolism of threonine and methionine was ignored
because of their very low uptake rates [67].
The precursor for the synthesis of lipids is acetyl-CoA. The
major lipid types are triacylglycerols, cholesterol, and
phospholipids. Brain contains virtually no triacylglycerol
[74,80]. Therefore, related synthesis pathways were not
taken into account. All cholesterol in the brain is pro-
duced by local synthesis in astrocytes (r136) [81], with no
supply from other organs [82]. Necessary cholesterol for
neurons is supplied from astrocytes (r137), forming a cho-
lesterol shuttle between the two cell types [81,83,84]. The
lack of cholesterol synthesis in neurons in the adult state
is probably due to its high energetic cost (r136).
The building blocks for phospholipids are fatty acids,
which are synthesized from acetyl-CoA (r140–r149) in
cytosol. Nonessential fatty acids (palmitate, oleate, stear-
ate) are synthesized de novo in both cell types (r140–r142,
r145–r147) [85]. Arachidonate and decosahexenoate, how-
ever, require uptake of the essential fatty acids linoleate
and linolenate respectively by the astrocytes (r141–r142),
which can be provided externally, eg. through diet. Neu-
rons are not capable of producing these two fatty acids,
instead they take up the ones synthesized and released by
astrocytes (r146–r147) [86,87]. These five fatty acids consti-
tute more than 90% of phospholipids [80,88], therefore
other fatty acid types were ignored because of their very
low percentage. Accordingly, fatty acid synthesis reactions
in both cell types were written on the basis of the molar
composition reported in [80] (r148–r149). The same com-
position was assumed for astrocytes and neurons since it
has been reported that these two cell types have very sim-
ilar fatty acid and lipid compositions [89]. Phospholipids
are synthesized from fatty acids and glycerol-3-phosphate,
which is a product of a dehydrogenation reaction (r150,
r158) [74,75]. Here, phospholipids are assumed to be com-
posed of phosphatidyl-choline, phosphatidyl-serine, and
phosphatidyl-ethanolamine, which together constitute
about 85% of brain phospholipids [74,80,89-91]. The
related reactions (r152–r157, r159–r164) were compiled from
[74,75,92]. Finally, the synthesis of lipid in both cell types
was expressed in terms of reactions whose stoichiometric
coefficients are based on the molar lipid compositions
reported in [80] (r165–r166).
Glycerol-3-phosphate formation reaction is cytosolic in
astrocytes (r150) [31], and mitochondrial in neurons (r158)
[31,93]. Since the malate-aspartate shuttle is not active in
astrocytes, another shuttle mechanism must be active in
this cell type to transport cytosolic NADH produced due
to a high rate of glycolysis to mitochondria. Following this
logic, the glycerol-3-phosphate shuttle was proposed to be
active in astrocytes [31], which is validated by the pres-
ence of cytosolic and mitochondrial versions of the
enzyme in astrocytes [35]. Therefore, the dehydrogena-
tion reaction in astrocytic mitochondria was added to the
model in reverse direction (r151), allowing the transfer of
cytosolic NADH to mitochondria in the form of FADH2.
The brain requires glutathione for the removal of reactive
oxygen species (ROS) such as H2O2. Glutathione is syn-
thesized from cysteine (r168, r177), which is derived from
cystine (r167). Because only astrocytes can take cystine up
from the blood vessel and convert it to cysteine, neurons
are dependent on astrocytes for protection against oxida-
tive stress [11,94,95]. In astrocytes, formed peroxides
(r169) are removed by glutathione (r170). The resulting oxi-
dized glutathione is converted back to the reduced form
by glutathione reductase (r171, r172), which requiresTheoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
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NADPH and is located in both cytosol and mitochondria
[27]. Alternatively, catalase can convert peroxides back to
oxygen in the brain (r173) [27]. Reduced glutathione can
be converted to cysteinyl-glycine in astrocytes (r174),
which is used as the cysteine supply to the neurons (r175,
r176). Then cysteine acts as precursor for neuronal glutath-
ione (r177). The following protection mechanism is the
same as in astrocytes (r178–r182).
Brain has a high glycogen content [96], and astrocytes
contain nearly all of it [97,98]. In normal physiological
conditions, however, the rate of glycogen phosphoryla-
tion to glucose-6-phosphate and the rate of glycogen syn-
thesis from glucose-6-phosphate were found to be equal
[98]. That is, there is no net effect of glycogen on brain
metabolism under normal physiological circumstances.
Therefore, we do not include glycogen in modeling of the
resting state. However, it is hypothesized that glycogen
may act as a buffer under stress conditions such as
hypoxia [98]. Therefore, astrocytic glycogen breakdown
reactions were included in the model in such a way that
they are only allowed to be active during hypoxia simula-
tion (r183–r184).
Other pathways such as nucleotide metabolism were not
taken into account since there is no detailed information
on the compartmentation of those pathways between the
two cell types, and no significant fluxes have been
reported through such pathways. One should also note
that an individual neuron may not have all the reactions
detailed above since individual neurons are specialized to
synthesize specific neurotransmitters. Here we consider a
population of neurons rather than individuals, thereby
aiming at the overall picture in the brain.
A hypothesis called ANLSH (astrocyte-neuron lactate
shuttle hypothesis) proposes the use of astrocyte-derived
lactate as energy substrate by neurons under activated
conditions [99] where there is a stimulus. In the first part
of our work, we model brain metabolism under resting
conditions in the absence of any stimulus. That is why we
did not consider any transfer of lactate from astrocytes to
neurons in our model for the analysis of basal physiolog-
ical behaviour. In the second part of the work, where we
model hypoxic behaviour, the lactate shuttle is again not
considered. The idea behind ANLSH is to supply lactate as
an oxidative substrate for neurons to keep the TCA cycle
active, as an energetic contribution to aerobic neuronal
metabolism. However, the hypoxic state is associated with
gradual inactivation of the TCA cycle with restricted aero-
bic metabolism. Additionally, neurons start to produce
lactate in this state owing to reduced oxygen uptake.
Therefore, neurons do not need to use astrocytic lactate
since they already produce it. As a result, hypoxic analysis
is performed without any lactate transfer between the two
cell types.
Model prediction: Flux distributions among key pathways
The constructed model was first utilized to simulate the
neuron-astrocyte flux distribution under resting condi-
tions based on the constraints (Table 1) detailed in the
Methods section. FBA using an objective function together
with the imposed constraints is employed owing to the
underdetermined nature of the reconstructed network, to
get an optimum flux distribution (see Methods section).
The common objective function of maximal biomass pro-
duction used in FBA applications of unicellular cells can
hardly be applied to multifunctional cells. Therefore, a
number of objective functions as listed in Additional File
3: Supplementary Table 2 were employed and the one that
gave best agreement with the literature data was identi-
fied. The major criteria used in the judgment of suitability
of the objective functions were a) agreement with the lit-
erature-based lactate release flux, b) getting an active
glutamate-glutamine cycle, c) getting active BCAA shut-
tles, and d) getting active fluxes for PPPs; as the related
reactions have been extensively discussed in the literature.
Simulations indicated that use of simultaneous maximi-
zation of glutamate/glutamine/GABA shuttling reactions
between astrocytes and neurons (r75, r78, r81) with subse-
quent minimization of the Euclidean norm of fluxes
result in a flux distribution in accordance with literature
data. The following results and discussions are, therefore,
based on this flux distribution. The deficits for other
employed objective functions (the points where they con-
tradict the used criteria) are given in Additional File 3:
Supplementary Table 2. Using the successful objective
function, flux results regarding the key pathways are
Table 1: Blood-brain barrier uptake rates of glucose, oxygen, 
ammonia, cystine and essential amino acids; and carbon dioxide 
release rate (μmol/g tissue/min). The related references for the 
rates are given under "Parameters used in the stoichiometric 
model" section. A: Astrocytes, N: Neurons, CMR: Cerebral 
Metabolic Rate
CMRGlucose
A 0.160
CMRGlucoses
N 0.160
CMRO2
A 0.530
CMRO2
N 1.230
CMRCO2
A 0.515–0.530
CMRCO2
N 1.193–1.230
CystineA 0.0045
AmmoniaA 0.0035
PhenyalanineN 0.0132
TryptophanN 0.0082
LeucineA 0.0145
IsoleucineA 0.0040
TyrosineN 0.0041
ValineA 0.0018
LysineN 0.0103Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
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depicted in Figure 2. Thus, the FBA results allowed us to
identify how the available fuels (glucose, essential amino
acids) are shared among the different pathways of the two
cell types, as demonstrated in Figure 2 and discussed
below.
An additional table is provided (Table 2) which shows the
maximum and minimum attainable values of the fluxes
or flux ratios used for verification in the model. Thereby,
it is shown that the model with the specified constraints is
flexible enough to attain different flux values, and the
chosen objective functions have enabled the calculated
flux values/ratios to be in accordance with literature.
Central Carbon metabolism
The ratio of neuronal TCA cycle flux to the total TCA cyle
flux, r22/(r22 + r58), is calculated as 0.35 by our approach,
which is in good agreement with the literature-reported
value of 30% [7,97,100]. This ratio also represents the rel-
ative oxidative metabolism of astrocytes. Therefore, our
simulations support the view that, albeit lower than that
of neurons, astrocytes have active oxidative metabolism
under the nonstimulated conditions in parallel with the
reported findings [97,101,102], rather than having only
anaerobic metabolism or very low oxidative metabolism.
On the other hand, the ratio of astrocytic ATP generation
for ATPase pump and maintenance (r37 + r75) to the total
ATP generation rate is 0.27, indicating the degree of rela-
tive ATP production in both cells, as consistent with the
above-stated fraction of oxidative metabolism. Addition-
ally, the percentage of model-based pyruvate carboxylase
Major metabolic fluxes (μmol/g tissue/min) in neuron-astrocyte coupling for resting conditions Figure 2
Major metabolic fluxes (μmol/g tissue/min) in neuron-astrocyte coupling for resting conditions. The fluxes were calculated 
with the objective of maximizing the glutamate/glutamine/GABA cycle fluxes between the two cell types with subsequent minimization of 
Euclidean norm of fluxes, using the uptake rates given in Table 1 as constraints. Thick arrows show uptake and release reactions. Dashed 
arrows indicate shuttling of metabolites between the two cell types. Only key pathway fluxes are represented here for simplicity. The flux 
distributions for all the reactions listed in Additional File 1 are given in Additional File 4:Supplementary Table 3.
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flux (r12) with respect to CMRglc (11.7%) matches very
well with reported results of around 10% [7,100,103].
This flux is only astrocytic and enables de novo synthesis of
TCA cycle intermediates in this cell type. The flux through
reaction, which represents the activity of the malate-aspar-
tate shuttle in neurons by transferring NADH from cytosol
to mitochondria (r68), is calculated as 0.34 μmole/g/min.
The magnitude of this flux is reported to be similar to that
of the flux through neuronal pyruvate dehydrogenase
(r49) [7]. Our results support this relationship since the
latter flux acquires a value of 0.29 μmole/g/min in our
simulations. The high flux also emphasizes the view that
the shuttle is of considerable importance to neurons
[30,31], contributing to ATP synthesis by transferring
NADH to mitochondria. It was reported that malic
enzyme is only astrocytic in physiological conditions
[44,63]. The calculated flux through the cytosolic malic
enzyme of astrocytes is 0.06 whereas that through the
mitochondrial one in neurons is zero, supporting the
physiological findings. The ratio of the rates of total TCA
cycle to total glucose consumption, (r22 + r58)/CMRglc, is
calculated as 1.51 by our approach, which is lower than
the reported values of approximately 2 [7,104]. The rea-
son behind this discrepancy is that the Acetyl-CoA
requirement for biosynthetic routes, especially for lipid
metabolism, was ignored in those studies although signif-
icant molar amount is needed for cholesterol (r136) and
fatty acid (r138–r140, r143–r145) syntheses. That is, some
portion of glycolytic Acetyl-CoA is diverted to lipid
metabolism leading to lower TCA fluxes. Therefore, our
simulation result is in accordance with the expectation
that the ratio rTCA,total/CMRglc must be lower than 2.
The present model results suggest that NADPH produc-
tion through the pentose phosphate pathway, r14 and r50,
is at the specified boundaries for both cell types. Regard-
ing the fluxes through the ROS pathway; the model calcu-
lates astrocytic peroxide formation rates as zero, implying
that the pathway is inactive in this cell type. This is in
accordance with the relatively lower oxidative metabolism
in astrocytes. For neurons, however, there is significant
peroxide formation, and hence glutathione is oxidized
and then reduced to remove oxidative stress. NADPH
used for oxidative stress reduction is 0.18 and 0.24
μmole/g/min in cytosol (r180) and in mitochondria (r181)
respectively.
The lactate release rate was calculated as 8.9% of glucose
flux. In terms of the carbon-mole, this stands for 4.5% of
glucose carbon through the lactate route, which is in the
vicinity of the reported values at rest [105-108]. This per-
centage becomes higher when higher leucine uptake rates
are considered as reported by others [70,105].
Glutamate-Glutamine Cycle and Other Cycles
The neuronal and glial compartments are known to be the
two major compartments of brain metabolism, and they
are metabolically linked with the glutamate-glutamine
cycle. This has led to detailed investigations of the flux
through this cycle, because it represents the hallmark of
cerebral metabolic compartmentation and it is closely
linked to the Krebs cycle [22,104,109].
The ratio between the glutamate-glutamine cycle and the
glucose consumption rate, r78/CMRglc, was calculated by
FBA as 0.68, which is in the range of reported values
(0.41–0.80) [7,44,104]. The ratio attains a value on the
upper border of the literature results (0.81), when the
GABA cycling flux is added to the glutamate-glutamine
cycling flux. Thus, the constructed stoichiometric model
leads to a reasonable prediction regarding the well-known
glutamate-glutamine cycle, which is essential for the func-
tioning and coupling of astrocytes and neurons and has
been of deep interest for researchers in this area
Table 2: Minimum and maximum attainable values for fluxes/flux ratios used in the model to verify the model compared to basal FBA 
and literature values. The results show that the model with the specified constraints is flexible enough to attain different flux values, 
but it was the chosen objective functions that resulted in flux values/ratios in accordance with literature. See the results & discussion 
part of the main text for detailed discussion of FBA results.
% Flux Ratio minimum maximum FBA of resting state* literature values in percentage
% Lactate release flux (r11) with respect to CMRglc 0 16 4.5/4.7 3–9 [105-108]
% Glutamate/Glutamine cycle flux (r78) with respect to CMRglc 0 68 68/56 40–80 [7; 44; 104]
rTCA,A/rTCA,total, r22/(r22 + r58) (percent relative oxidative 
metabolism of astrocytes)
12 42 35/35.4 30# [7; 97; 100]
% total lipid synthesis with respect to CMRglc 0.6 3.8 2.8/2.8 2 [74]
% total PPP flux with respect to CMRglc 0 5.6 5.6/5.6 3–6 [151; 152]
% pyruvate carboxylase flux (r12) with respect to CMRglc 2.8 45 11.7/10.8 10 [7; 100; 103]
* The second values in this column are results of resting state simulation with 40%–60% partitioning of glucose utilization between neurons and 
astrocyte respectively, corresponding to glucose uptake rates of 0.128 μmole/g/min and 0.192 μmole/g/min. The results show that the flux ratios 
are robust to the relative glucose uptake rates by the two cell types.
#The literature value for this percentage is based on experimental results on human [7] and rat [100] as reported in Table 1 and corresponding 
footnotes of [97]. However, others [156] calculated a lower percentage (19%) for human, based on the same experimental data.Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
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[7,24,104,110,111]. Additionally, it has been reported
that glutamine efflux to the extracellular space from astro-
cytes ranges between 0.002 and 0.080 μmol/g/min [44].
The value calculated by the present model (0.011 μmol/g/
min) is in agreement with this range.
The cycles other than the glutamate-glutamine cycle were
calculated to have lower flux values. Serine-glycine cycling
operates with a flux of 0.01 μmol/g/min. The flux through
each of the BCAA cycles, which are directly linked to the
glutamate pool, is about 33% of the glutamate-glutamine
cycle flux. In this way, they contribute to the glutamate-
glutamine cycle flux. This contribution for leucine alone
was reported as 25–30% [112] in parallel with our predic-
tions. For valine and isoleucine, however, the reported
values are much lower [64]. Also, a much higher astrocytic
transamination rate of leucine (r99) than the decarboxyla-
tion rate of KIC (r100) has been reported [64]. The ratio of
these fluxes (r99/r100) obtained by the present model is
more than 5, consistent with physiological expectation.
The directions of the aspartate and alanine cycle were
from neurons to astrocytes, contributing to the astrocytic
glutamate pool, with fluxes of 0.092 and 0.025 μmol/g/
min respectively. Unlike the alanine cycle, the aspartate
cycle acquires a relatively higher flux, which needs to be
confirmed by experimental studies.
The above-discussed FBA results show which metabolic
interactions were active between astrocytes and neurons
under resting states, and the redistribution of correspond-
ing fluxes in both cell types is indicative of the relative
activity of the interactions.
Lipid Metabolism
Inclusion of lipid metabolism is especially important for
ATP, NADPH and Acetyl-CoA balances to be closed. The
model-based fluxes indicate that lipid synthesis under
steady state conditions is possible in astrocytes, with a rate
corresponding to 2.8% of glucose flux. This is in accord-
ance with the literature value [74], which reports that
about 2% of the glucose flux goes to lipid metabolism.
Our model does not calculate any flux through neuronal
lipid metabolism. This implies either a deficit of the
model or the absence of any significant lipid synthesis rate
in mature neurons.
In silico Neurotransmitter Production Capabilities
To identify the maximum production capabilities of the
brain cells for the major neurotransmitters, FBA was
applied to the constructed stoichiometric model using the
maximization of each of these neurotransmitters as the
objective function. The resultant fluxes were compared
with those obtained in the simulation of the resting con-
dition analyzed above. Since neurotransmitters are pro-
duced in neurons and released to synaptic clefts, the flux
values of the reactions that carry them from neurons to
the extracellular space, or to astrocytes to clear them from
synaptic clefts, were used in the analysis. Figure 3 depicts
the results comparatively. Aspartate has the highest pro-
duction rate under resting conditions followed by gluta-
mate and GABA, whereas all the others have minute
fluxes. Serotonin, GABA and dopamine were found to be
synthesized at rates close to their theoretical maxima. For
all the remaining neurotransmitters, the maximum pro-
duction capability was several folds higher than their
basal levels. For glycine, no finite maximum value could
be identified, which implies partial uncoupling of this
pathway from the rest of the network. Additional experi-
mental and/or clinical research is necessary to verify these
in silico predictions.
Potential of the reconstructed model in the analysis of 
neural diseases
Many diseases of the brain have been reported to result
from neurovascular coupling disorders, where mainly
oxygen deficiency leads to a cascade of events. A decrease
in cerebral perfusion due to arterial obstruction (loss of
arterial compliance) leads to the formation of hypoxic
regions in the brain as encountered in the pathophysiol-
ogy of aging and several psychiatric disorders as well as
headache. Hypoxic regions in the brain have been known
to cause major disturbances in the electrical activity of the
brain (as in epilepsy) or lead to progressive diseases such
as dementia, Alzheimer's and even emotional distur-
bances. Hence, as a good predictor of our model, we chose
Neurotransmitter production rates (μmole/g/min) under  resting conditions in comparison with their maximum values Figure 3
Neurotransmitter production rates (μmole/g/min) 
under resting conditions in comparison with their 
maximum values. The rates for resting conditions were 
calculated with the objective maximizing glutamate/
glutamine/GABA cycle fluxes between the two cell types 
with subsequent minimization of Euclidean norm of fluxes. 
The maximum value that a neurotransmitter production flux 
can attain was calculated for comparison by maximizing each 
of these fluxes one by one using linear programming.
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to simulate the effects of hypoxia in hope that it can be
explained by stoichometric modeling approaches.
It has been reported that deficient cells exhibit a flux pro-
file closest to the healthy (non-deficient) flux distribution
[113,114]. This finding was used as a basis to simulate
oxygen deprivation of cerebral and astrocytic metabolism.
Oxygen flux was gradually decreased in small intervals,
and the new flux distributions were calculated using
quadratic programming with the objective function of
minimizing the Euclidean distance from the flux distribu-
tion of the healthy case, an approach called Minimization
of Metabolic Adjustment, MOMA [114]. Glycogen break-
down reactions were made active in hypoxic simulations
[98]. None of the fluxes in Table 1 that were used as con-
straints in the analysis of resting conditions were used in
the simulation of hypoxia. Thereby, the effects of hypoxia
on the uptake rates were also accounted for. Additionally,
the flux through the pentose phosphate pathway in both
cell types and GABA flux as well as RQ were left uncon-
strained. The only constraint was due to MOMA, i.e.
obtaining a flux distribution as close to the healthy-case
flux distribution as possible. The changes of the major
fluxes in response to oxygen uptake deficiency are
depicted in Figures 4 and 5. Such a simulation reflects the
effect of hypoxic conditions on brain metabolism. A lac-
tate efflux by neurons was considered in these simulations
since oxygen deprivation results in the activation of anaer-
obic metabolism in this cell type.
Simulation of cerebral hypoxia (up to zero CMRO2)
reveals more than tripling of astrocytic lactate production
as well as significant neuronal production, implying the
sharp activation of anaerobic metabolism (Figure 4). That
is why the TCA cycle in both cells is found to exhibit a par-
allel gradual inactivation. In fact, these are the general
Cerebral hypoxia Figure 4
Cerebral hypoxia. Effect of oxygen deprivation of brain cells on metabolic fluxes calculated by MOMA approach. All the x-
axes represent the oxygen flux, CMRO2, available to brain cells. It is changed from anoxic level (no oxygen uptake) to the basal 
level (1.760 μmole/g/min). The title of each sub-figure includes the reaction number of the plotted flux, as given in Additional 
File 1.
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characteristics of hypoxic cells) [115,116]. The decrease in
malate shuttling rate in neurons (r68) in response to lower
oxygen uptake flux, as shown in Figure 4, means less
cytosolic NADH contribution to oxidative phosphoryla-
tion in mitochondria, another indication of hypoxic func-
tioning. This is in accordance with the finding that
inhibition of malate shuttling substantially reduces oxida-
tive metabolism in neurons [117]. On the other hand,
there is almost a doubling of glucose uptake rate through
neurons, whereas the astrocytic uptake rate becomes zero
at about 65% oxygen deficiency, a result that needs verifi-
cation. Increased glucose uptake rates during hypoxia to
maintain ATP levels have been reported [118,119].
Increase in the glucose uptake rate during anoxia was also
reported as a mechanism to cope with Alzheimer's disease
[120]. The flux through astrocytic glycogen breakdown
becomes active in the initial phase of the hypoxic state,
and increases considerably as the anoxic state is
approached. The importance of glycogen metabolism in
hypoxia has been stated [96]. One other clear feature is
the impairment of the transfer flux of glutamate from neu-
rons to astrocytes (r75) and the concurrent significant
decrease in the return part of the cycle flux (r78). Such an
impairment has already been described [10]. The signifi-
cantly decreased flux through the glutamate-glutamine
and alanine cycles and the ceased fluxes of the BCAA,
Aspartate and GABA cycles are consistent with the hypoth-
esis that hypoxia leads to lower trafficking between astro-
cytes and neurons)[115]. The abrupt effect of oxygen
deficiency on brain metabolism is also reflected by the
huge change in the objective function value (Figure 4).
Since the effect of hypoxia on only astrocytes was studied
in detail [116], their oxygen deprivation was simulated
separately here, by providing neurons with the baseline
oxygen flux and restricting astrocytic oxygen uptake. The
effect of hypoxia on astrocytic cells (Figure 5) is found to
be relatively mild, as manifested by the magnitude of
change of the objective function value. That is, astrocytes
cope more readily with hypoxia than neurons, as demon-
strated by several researchers [116,121,122]. Simulations
indicate that these cells have the potential to function
anaerobically (with no oxygen flux), which is already
known as one of their characteristics [123,124]. However,
glutamate transfer from neurons to astrocytes stops func-
tioning after a certain level of allowed CMRO2 (0.35
μmole/g/min), similar to that observed in the simulation
of cerebral hypoxia. This, compared with the results
above, suggests that it is the degree of oxidative metabo-
lism of the astrocytes that monitors the activity of the
cycle. In other words, although no perturbation was
applied to neurons, astrocytic oxygen deprivation led to
the cessation of the uptake of neuronal glutamate by
astrocytes. Simulation of neuronal hypoxia (results not
shown) confirms this in silico prediction since a significant
increase, rather than a decrease, in glutamate uptake rates
by astrocytes was calculated in this case. In addition,
results suggest relative uncoupling of ATP production
mechanisms of the two cells since the neuronal ATP pro-
duction rate and TCA cycle rate are found to be almost
unaffected (Figure 5). Interestingly, astrocytic hypoxia
triggers neuronal anaerobic metabolism as manifested by
the low lactate flux (max. 0.02 μmole/g/min). One simu-
lation result that conflicts with literature results is a
decrease rather than an increase in astrocytic glucose
uptake flux in response to hypoxic stress. Instead, an
increase in glycogen breakdown flux is observed in astro-
cytes. Nevertheless, the literature data are for independent
cultivation of astrocytes without neurons [116,121,122].
Here, we simulate astrocytic hypoxia in the presence of
neurons, which can work as a metabolic support for astro-
cytes preventing an increase in their glucose uptake rate.
The present results demonstrate the power of the con-
structed model to simulate disease behaviour on the flux
level, and its potential to analyze cellular metabolic
behaviour  in silico. Preliminary analysis of some other
common metabolic diseases such as hyperammonaemia,
maple syrup urine disease and phenylketonuria by this
approach is also promising (unpublished results).
Conclusion
Stoichiometric flux analysis techniques have been success-
fully applied to the analysis of mammalian cells [6,125-
128]. Compared to a previous attempt at stoichiometric
modeling of brain metabolism [6], the reconstructed
model presented here not only includes the well-known
glutamate-glutamine cycle, but also takes BCAA coupling,
aspartate, alanine, serine, glycine, glutathione and GABA
couplings, and neurotransmitter and lipid synthesis reac-
tions, into consideration as well, for the first time in the
literature. We thus attempted to model the basal physio-
logical behaviour of brain cells where astrocytes and neu-
rons are tightly coupled. By employing a reasonable
objective function (simultaneous maximization of the
GABA/Glutamate/Glutamine cycle fluxes with subse-
quent minimization of the sum of the fluxes) we have
obtained flux values/ratios in accordance with the litera-
ture. The predictive power of the constructed model for
the key flux distributions, especially central carbon
metabolism and the glutamate-glutamine cycle fluxes,
and for the capabilities of neuron and astrocyte metabo-
lism is promising. This model can additionally be used in
the analysis of metabolic neurological diseases since the
use of similar stoichiometric modeling approaches for
metabolic diseases has already been demonstrated
[113,125,129,130]. Such models also have the potential
to be used for hypothesis testing. Although the present
stoichiometric model gave some unexpected results, such
as the prediction of a high aspartate flux between the twoTheoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
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cell types, such limitations are already known for stoichi-
ometric models that only depend on the stoichiometry of
reactions and measured uptake fluxes as constraints, and
therefore the regulatory events occurring in the cell cannot
be incorporated. Integration of regulation into such mod-
els has been attempted [131,132], but the appropriate
method for such implementation still remains to be estab-
lished.
Methods
Computational protocol
The stoichiometric coefficients of the compiled reactions
and their reversibility information were used to constrain
the flux solution space;
S × v = 0 (1)
vmin ≤ v ≤ vmax (2)
where S is an m by n stoichiometric matrix with m being
the number of metabolites (213) and n being the number
of reactions covering the pathway and the exchange reac-
tions (214), v is the flux vector to be identified, and vmin
&vmax are the lower and upper bounds of the fluxes based
on the reversibility information. The uptake rates of extra-
cellular metabolites (Table 1) from the blood brain bar-
rier were all specified to constrain the model further. To
this aim, the lower and upper bounds of the correspond-
ing reactions were set to the reported values given in Table
1. The degrees of freedom of the reconstructed reaction
network, S, show the difference between the number of
independent equations (i.e. independent metabolites;
also equals to the rank of matrix S) and number of
Astrocytic hypoxia Figure 5
Astrocytic hypoxia. Effect of oxygen deprivation of astrocytes on metabolic fluxes calculated by MOMA approach. All the x-
axes represent the oxygen flux available to astrocytic cells. It is changed from anoxic level (no oxygen uptake) to the basal level 
(0.53 μmole/g/min). (no lactate release from neurons). The title of each sub-figure includes the reaction number of the plotted 
flux, as given in Additional File 1.
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unknowns (i.e. reaction rates) in the linear equation sys-
tem defined by equation (1), and it is calculated as 47. Lit-
erature values of 15 fluxes (Table 1) were specified as
constraints in FBA, resulting a remaining degrees of free-
dom of 32. Flux balance analysis (FBA), a solution tech-
nique for underdetermined systems that utilizes linear or
quadratic programming to find an optimum solution
[133], was used to identify metabolic flux distributions in
and between the two types of brain cells based on the
applied constraints. To express this mathematically,
min f Tv (3)
subject to equations (1) and (2), with all entries of the
row vector, f, being zero except the entries corresponding
to the fluxes to be maximized. FBA has so far been mainly
applied to microbial cells, for which biomass growth was
used as standard objective function in the optimization
problem. For mammalian metabolism, however, there is
no standard objective function. Therefore, the optimum
solution for this problem was sought under different can-
didate objective functions that are listed in Additional File
3: Supplementary Table 2 with corresponding reasonings
for their selection. Thereby, we tried to identify a suitable
objective function for brain metabolism.
On the other hand, in the FBA approach, there is the pos-
sibility of multiple optima, different flux distributions
with the same optimal objective flux [134,135]. To elimi-
nate the multiplicity of flux values due to this problem,
the system was subjected to a second optimization: the
minimization of the squared sum of all fluxes, known as
minimization of the Euclidean norm, was used as an sec-
ond objective function for FBA to ensure efficient chan-
neling of all the fluxes through all pathways [136]. That is,
by fixing the objective function value of the first optimiza-
tion; minimization of sum of fluxes was applied, thereby
selecting the flux distribution with the smallest sum of
fluxes among all alternate optima. To express the second
optimization mathematically,
subject to the constraints by equations (1), (2), and addi-
tionally to the constraint through the first optimization:
f Tv = objfun (5)
where objfun is the optimal value of the objective function
obtained in the linear optimization problem of (3).
The underlying hypothesis is that cells aim to fulfill their
functions with minimal effort since increasing the flux
through any reaction will require an extra investment such
as increasing enzyme levels [137]. Derivatives of this
approach have been proposed and shown to be a suitable
objective function for mammalian [137] and bacterial
[138] cells.
Optimizations were performed in the MATLAB 7.0 envi-
ronment with a MATLAB interface to CLP solver
[139]developed by Johan Löfberg [140]. Flux values of all
reactions in the resting state with the identified objective
function, and in the anoxic state (complete lack of oxygen
uptake), are given in Additional File 4: Supplementary
Table 3. Matlab routines used in the simulations are avail-
able as Additional File 5.
Parameters used in the stoichiometric model
Literature-based uptake fluxes of glucose, oxygen, ammo-
nia, cystine and essential amino acids as well as carbon
dioxide release flux (Table 1) were used as constraints on
the reconstructed model in the simulation of fluxes by
FBA.
Glucose and oxygen are the main substrates fueling both
astrocytes and neurons, and their cerebral metabolic rates
(CMR) are closely related. The arithmetic average of liter-
ature-reported cerebral glucose utilization rates for
human brain under resting conditions (0.32 μmol/g tis-
sue/min) [7,74,104,141,142] was used in the model.
Many studies have reported the ratio of CMRO2/CMRglc in
normal resting brain as about 5.5 [37,74,143]. Hence, the
cerebral oxygen uptake rate was taken as 1.76 μmol/g tis-
sue/min. Regarding individual uptake rates of glucose by
neurons and astrocytes, it has been reported that about
half of blood-borne glucose phosphorylation takes place
in astrocytes in vivo [97,144]. Therefore, equal glucose
uptake rates are assumed for each cell type. Thirty percent
of total oxygen consumption in brain cortex is attributed
to astrocytic cells [7,44,97]. Individual oxygen uptake
rates of neurons and astrocytes were calculated on the
basis of this percentage. Additionally, since it is known
that the respiratory quotient (rCO2/rO2) of brain is very
close to one with values reported between 0.91–1.00
[108,145], the CO2 production rate is constrained so as to
give the reported RQ range for both cell types.
Amino acid uptake rates [67] were compartmentalized as
discussed in the main text and listed in Table 1. For
ammonia, the astrocyte is assumed to be the compart-
ment for the uptake mechanism [146-148], and a rate of
0.0035 μmol/g tissue/min has been reported [149]. The
cystine uptake rate was calculated from the arteriovenous
concentration difference (9 μmol/L, [150]) and the cere-
bral blood flow rate in humans (0.50 ml/g/min, [142]).
Two more constraints were added to the model to obtain
more reliable flux distributions by reducing the solution
space. The flux through the pentose phosphate pathway
min vi
i
2 ∑ (4)Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
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for astrocytes has been reported as 6% of the glucose con-
sumption flux [151], while values up to 5% have been
reported for neurons [152,153]. These percentages were
used as the upper bounds for the flux through this path-
way. Additionally, the reports [154,155] that GABA
cycling flux is about 25% of glutamate-glutamine cycle
flux were employed to constrain r82 as 25% of r78. This
enabled the GABA pathway to be more tightly coupled
with the overall network.
All the reported rates compiled from the literature (Table
1) are used as the input fluxes to the constructed model,
and they are used as the constraints on the method
employed, FBA, to obtain the corresponding metabolic
flux distributions subject to the selected objective func-
tion. Since the degrees of freedom of the model is very
high (47), we can safely specify/constrain a number of
fluxes without harming the underdetermined nature of
the metabolic system. Indeed, Table 2 gives the maximum
and minimum attainable values of the fluxes or flux ratios
used for verification in the model, indicating that the
model with the specified constraints is flexible enough to
attain different flux values. Specifying as many unknowns
as possible is also necessary owing to the availability of
alternate optima in such models, which otherwise may
result in ambiguous values for some fluxes in the model.
The rates were compiled from different sources since it
was not possible to obtain all measurements from a single
source. Studies reporting analysis of these rates in the
same system, which will be facilitated by novel high
throughput measurement techniques, will lead to more
accurate results, strengthening the role of such models in
medical modeling.
Abbreviations
FBA: Flux balance analysis, 
MOMA: Minimization of metabolic adjustment, 
CNS: Central nervous system, 
GABA: γ-aminobutyric acid, 
TCA: Tricarboxylic acid, 
CoA: Coenzyme-A, 
DOPA: Dihydroxyphenylalanine, 
CMR: Cerebral metabolic rate, 
BCAA: Branched chain amino acids, 
KIC: α-ketoisocapriate, 
KIV: α-ketoisovalerate, 
KMV: α-keto-β-methylvalerate, 
ROS: Reactive oxygen species, 
PPP: Pentose phosphate pathway, 
RQ: Respiratory Quotient, 
OX-PHOS: Oxidative Phosphorylation.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
KOU and AA designed the research. TC and SA recon-
structed the model and performed the simulations. TC,
SA, HS, AA and KOU analyzed the results. TC, SA, AA and
KOU wrote the manuscript. All authors read and
approved the final manuscript.
Additional material
Additional file 1
Reaction Set of Metabolic Reconstruction for Astrocytes and Neurons.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4682-4-48-S1.pdf]
Additional file 2
Supplementary Table 1 – Metabolic differences in two cell types reflected 
in our model.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4682-4-48-S2.pdf]
Additional file 3
Employed objective functions with corresponding reasonings.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4682-4-48-S3.pdf]
Additional file 4
Supplementary Table 3 – Flux distributions for all reactions in resting and 
anoxic states.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4682-4-48-S4.xls]
Additional file 5
Matlab routines used in the simulations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4682-4-48-S5.zip]Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
Page 15 of 18
(page number not for citation purposes)
Acknowledgements
The research was supported by the Boğaziçi University Research Fund 
through project 04A501, 04S101 and by DPT through 03K120250. The 
doctoral fellowship for Tunahan Çakir, provided within the framework of 
the integrated Ph.D. program, BDP, sponsored by BAYG-TUBITAK, is 
gratefully acknowledged. Prof. Lockwood is acknowledged for providing 
the authors with his article.)
References
1. Magistretti PJ, Pellerin L: Cellular mechanisms of brain energy
metabolism and their relevance to functional brain imaging.
Philos Trans R Soc Lond B Biol Sci 1999, 354:1155-1163.
2. Raichle ME: Functional brain imaging and human brain func-
tion.  J Neurosci 2003, 23:3959-3962.
3. Savoy RL: History and future directions of human brain map-
ping and functional neuroimaging.  Acta Psychol (Amst) 2001,
107:9-42.
4. Ugurbil K, Adriany G, Andersen P, Chen W, Gruetter R, Hu X,
Merkle H, Kim DS, Kim SG, Strupp J, Zhu XH, Ogawa S: Magnetic
resonance studies of brain function and neurochemistry.
Annu Rev Biomed Eng 2000, 2:633-660.
5. Aubert A, Costalat R: A model of the coupling between brain
electrical activity, metabolism, and hemodynamics: applica-
tion to the interpretation of functional neuroimaging.  Neu-
roimage 2002, 17:1162-1181.
6. Chatziioannou A, Palaiologos G, Kolisis FN: Metabolic flux analysis
as a tool for the elucidation of the metabolism of neurotrans-
mitter glutamate.  Metab Eng 2003, 5:201-210.
7. Gruetter R, Seaquist ER, Ugurbil K: A mathematical model of
compartmentalized  neurotransmitter metabolism in the
human brain.  Am J Physiol Endocrinol Metab 2001, 281:E100-12.
8. Tiveci S, Akin A, Cakir T, Saybasili H, Ulgen K: Modelling of cal-
cium dynamics in brain energy metabolism and alzheimer's
disease.  Comput Biol Chem 2005, 29:151-162.
9. Vafaee MS, Gjedde A: Model of blood-brain transfer of oxygen
explains nonlinear flow-metabolism coupling during stimula-
tion of visual cortex.  J Cereb Blood Flow Metab 2000, 20:747-754.
10. Benarroch EE: Neuron-astrocyte interactions: partnership for
normal function and disease in the central nervous system.
Mayo Clin Proc 2005, 80:1326-1338.
11. Hertz L, Zielke HR: Astrocytic control of glutamatergic activ-
ity: astrocytes as stars of the show.  Trends Neurosci 2004,
27:735-743.
12. Deitmer JW: Glial strategy for metabolic shuttling and neuro-
nal function.  Bioessays 2000, 22:747-752.
13. Hertz L, Dringen R, Schousboe A, Robinson SR: Astrocytes: gluta-
mate producers for neurons.  J Neurosci Res 1999, 57:417-428.
14. Sonnewald U, Westergaard N, Schousboe A: Glutamate transport
and metabolism in astrocytes.  Glia 1997, 21:56-63.
15. Fields RD, Stevens-Graham B: New insights into neuron-glia
communication.  Science 2002, 298:556-562.
16. Giaume C, Tabernero A, Medina JM: Metabolic trafficking
through astrocytic gap junctions.  Glia 1997, 21:114-123.
17. Laming PR, Kimelberg H, Robinson S, Salm A, Hawrylak N, Muller C,
Roots B, Ng K: Neuronal-glial interactions and behaviour.  Neu-
rosci Biobehav Rev 2000, 24:295-340.
18. Kauffman KJ, Prakash P, Edwards JS: Advances in flux balance
analysis.  Curr Opin Biotechnol 2003, 14:491-496.
19. Varma A, Palsson BO: Metabolic flux balancing: basic concepts,
scientific and pratctical use.  Bio/technology 1994, 12:994-998.
20. Chih CP, Lipton P, Roberts ELJ: Do active cerebral neurons
really use lactate rather than glucose?  Trends Neurosci 2001,
24:573-578.
21. Dienel GA, Hertz L: Glucose and lactate metabolism during
brain activation.  J Neurosci Res 2001, 66:824-838.
22. Gjedde A, Marrett S: Glycolysis in neurons, not astrocytes,
delays oxidative metabolism of human visual cortex during
sustained checkerboard stimulation in vivo.  J Cereb Blood Flow
Metab 2001, 21:1384-1392.
23. Mangia S, Giove F, Bianciardi M, Di Salle F, Garreffa G, Maraviglia B:
Issues concerning the construction of a metabolic model for
neuronal activation.  J Neurosci Res 2003, 71:463-467.
24. Hertz L: Intercellular metabolic compartmentation in the
brain: past, present and future.  Neurochem Int 2004, 45:285-296.
25. Minich T, Yokota S, Dringen R: Cytosolic and mitochondrial iso-
forms of nadp+-dependent isocitrate dehydrogenases are
expressed in cultured rat neurons, astrocytes, oligodendro-
cytes and microglial cells.  J Neurochem 2003, 86:605-614.
26. Bixel MG, Engelmann J, Willker W, Hamprecht B, Leibfritz D: Metab-
olism of [u-(13)c]leucine in cultured astroglial cells.  Neuro-
chem Res 2004, 29:2057-2067.
27. Dringen R, Pawlowski PG, Hirrlinger J: Peroxide detoxification by
brain cells.  J Neurosci Res 2005, 79:157-165.
28. Vogel R, Hamprecht B, Wiesinger H: Malic enzyme isoforms in
astrocytes: comparative study on activities in rat brain tissue
and astroglia-rich primary cultures.  Neurosci Lett 1998,
247:123-126.
29. Berkich DA, Xu Y, LaNoue KF, Gruetter R, Hutson SM: Evaluation
of brain mitochondrial glutamate and alpha-ketoglutarate
transport under physiologic conditions.  J Neurosci Res 2005,
79:106-113.
30. Kala G, Hertz L: Ammonia effects on pyruvate/lactate produc-
tion in astrocytes – interaction with glutamate.  Neurochem Int
2005, 47:4-12.
31. McKenna MC, Waagepetersen HS, Schousboe A, Sonnewald U: Neu-
ronal and astrocytic shuttle mechanisms for cytosolic-mito-
chondrial transfer of reducing equivalents: current evidence
and pharmacological tools.  Biochem Pharmacol 2006, 71:399-407.
32. Norenberg MD, Huo Z, Neary JT, Roig-Cantesano A: The glial
glutamate transporter in hyperammonemia and hepatic
encephalopathy: relation to energy metabolism and gluta-
matergic neurotransmission.  Glia 1997, 21:124-133.
33. Zwingmann C, Leibfritz D: Regulation of glial metabolism stud-
ied by 13C-NMR.  NMR Biomed 2003, 16:370-399.
34. Lo AS, Liew C, Ngai S, Tsui SK, Fung K, Lee C, Waye MM: Develop-
mental regulation and cellular distribution of human
cytosolic malate dehydrogenase (mdh1).  J Cell Biochem 2005,
94:763-773.
35. Yang J, Suder P, Silberring J, Lubec G: Proteome analysis of mouse
primary astrocytes.  Neurochem Int 2005, 47:159-172.
36. Arkblad EL, Egorov M, Shakhparonov M, Romanova L, Polzikov M,
Rydström J: Expression of proton-pumping nicotinamide
nucleotide transhydrogenase in mouse, human brain and c
elegans.  Comp Biochem Physiol B Biochem Mol Biol 2002, 133:13-21.
37. Gjedde A, Marrett S, Vafaee M: Oxidative and nonoxidative
metabolism of excited neurons and astrocytes.  J Cereb Blood
Flow Metab 2002, 22:1-14.
38. Benjamin AM, Quastel JH: Metabolism of amino acids and
ammonia in rat brain cortex slices in vitro: a possible role of
ammonia in brain function.  J Neurochem 1975, 25:197-206.
39. Yudkoff M, Nissim I, Pleasure D: Astrocyte metabolism of
[15n]glutamine: implications for the glutamine-glutamate
cycle.  J Neurochem 1988, 51:843-850.
40. Hassel B, Bachelard H, Jones P, Fonnum F, Sonnewald U: Trafficking
of amino acids between neurons and glia in vivo. effects of
inhibition of glial metabolism by fluoroacetate.  J Cereb Blood
Flow Metab 1997, 17:1230-1238.
41. Westergaard N, Sonnewald U, Unsgard G, Peng L, Hertz L, Schous-
boe A: Uptake, release, and metabolism of citrate in neurons
and astrocytes in primary cultures.  J Neurochem 1994,
62:1727-1733.
42. Attwell D, Laughlin SB: An energy budget for signaling in the
grey matter of the brain.  J Cereb Blood Flow Metab 2001,
21:1133-1145.
43. Eriksson G, Peterson A, Iverfeldt K, Walum E: Sodium-dependent
glutamate uptake as an activator of oxidative metabolism in
primary astrocyte cultures from newborn rat.  Glia 1995,
15:152-156.
44. Lebon V, Petersen KF, Cline GW, Shen J, Mason GF, Dufour S, Behar
KL, Shulman GI, Rothman DL: Astroglial contribution to brain
energy metabolism in humans revealed by 13c nuclear mag-
netic resonance spectroscopy: elucidation of the dominant
pathway for neurotransmitter glutamate repletion and
measurement of astrocytic oxidative metabolism.  J Neurosci
2002, 22:1523-1531.
45. McKenna MC, Stevenson JH, Huang X, Hopkins IB: Differential dis-
tribution of the enzymes glutamate dehydrogenase and
aspartate aminotransferase in cortical synaptic mitochon-
dria contributes to metabolic compartmentation in cortical
synaptic terminals.  Neurochem Int 2000, 37:229-241.Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
Page 16 of 18
(page number not for citation purposes)
46. Waagepetersen HS, Sonnewald U, Schousboe A: Compartmenta-
tion of glutamine, glutamate, and GABA metabolism in neu-
rons and astrocytes: functional implications.  Neuroscientist
2003, 9:398-403.
47. Cruz F, Cerdan S: Quantitative 13C NMR studies of metabolic
compartmentation in the adult mammalian brain.  NMR
Biomed 1999, 12:451-462.
48. Smith CUM: Elements of molecular neurobiology John Wiley and Sons;
2002. 
49. Larsson OM, Schousboe A: Kinetic characterization of GABA-
transaminase from cultured neurons and astrocytes.  Neuro-
chem Res 1990, 15:1073-1077.
50. Griffin JL, Keun H, Richter C, Moskau D, Rae C, Nicholson JK: Com-
partmentation of metabolism probed by [2-13c]alanine:
improved 13C NMR sensitivity using a cryoprobe detects
evidence of a glial metabolon.  Neurochem Int 2003, 42:93-99.
51. Waagepetersen HS, Sonnewald U, Larsson OM, Schousboe A: A pos-
sible role of alanine for ammonia transfer between astro-
cytes and glutamatergic neurons.  J Neurochem 2000,
75:471-479.
52. Zwingmann C, Richter-Landsberg C, Brand A, Leibfritz D: NMR
spectroscopic study on the metabolic fate of [3-(13)c]alanine
in astrocytes, neurons, and cocultures: implications for glia-
neuron interactions in neurotransmitter metabolism.  Glia
2000, 32:286-303.
53. Verleysdonk S, Hamprecht B: Synthesis and release of l-serine by
rat astroglia-rich primary cultures.  Glia 2000, 30:19-26.
54. Verleysdonk S, Martin H, Willker W, Leibfritz D, Hamprecht B:
Rapid uptake and degradation of glycine by astroglial cells in
culture: synthesis and release of serine and lactate.  Glia 1999,
27:239-248.
55. Yamasaki M, Yamada K, Furuya S, Mitoma J, Hirabayashi Y, Watanabe
M: 3-phosphoglycerate dehydrogenase, a key enzyme for l-
serine biosynthesis, is preferentially expressed in the radial
glia/astrocyte lineage and olfactory ensheathing glia in the
mouse brain.  J Neurosci 2001, 21:7691-7704.
56. Sakai K, Shimizu H, Koike T, Furuya S, Watanabe M: Neutral amino
acid transporter asct1 is preferentially expressed in l-ser-
synthetic/storing glial cells in the mouse brain with transient
expression in developing capillaries.  J Neurosci 2003,
23:550-560.
57. Hertz L: Astrocytic amino acid metabolism under control
conditions and during oxygen and/or glucose deprivation.
Neurochem Res 2003, 28:243-258.
58. Farrant M: Amino acids: inhibitory.  In Neurotransmitters, Drugs And
Brain Function Edited by: Webster R. John Wiley and Sons;
2001:225-250. 
59. Sato K, Yoshida S, Fujiwara K, Tada K, Tohyama M: Glycine cleav-
age system in astrocytes.  Brain Res 1991, 567:64-70.
60. Dringen R, Verleysdonk S, Hamprecht B, Willker W, Leibfritz D,
Brand A: Metabolism of glycine in primary astroglial cells: syn-
thesis of creatine, serine, and glutathione.  J Neurochem 1998,
70:835-840.
61. Sakata Y, Owada Y, Sato K, Kojima K, Hisanaga K, Shinka T, Suzuki Y,
Aoki Y, Satoh J, Kondo H, Matsubara Y, Kure S: Structure and
expression of the glycine cleavage system in rat central nerv-
ous system.  Brain Res Mol Brain Res 2001, 94:119-130.
62. Bixel MG, Hutson SM, Hamprecht B: Cellular distribution of
branched-chain amino acid aminotransferase isoenzymes
among rat brain glial cells in culture.  J Histochem Cytochem 1997,
45:685-694.
63. Lieth E, LaNoue KF, Berkich DA, Xu B, Ratz M, Taylor C, Hutson SM:
Nitrogen shuttling between neurons and glial cells during
glutamate synthesis.  J Neurochem 2001, 76:1712-1723.
64. Yudkoff M: Brain metabolism of branched-chain amino acids.
Glia 1997, 21:92-98.
65. Yudkoff M, Daikhin Y, Nelson D, Nissim I, Erecinska M: Neuronal
metabolism of branched-chain amino acids: flux through the
aminotransferase pathway in synaptosomes.  J Neurochem
1996, 66:2136-2145.
66. Platell C, Kong SE, McCauley R, Hall JC: Branched-chain amino
acids.  J Gastroenterol Hepatol 2000, 15:706-717.
67. Smith QR: Transport of glutamate and other amino acids at
the blood-brain barrier.  J Nutr 2000, 130:1016S-22S.
68. Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD:
Computational prediction of human metabolic pathways
from the complete human genome.  Genome Biol 2005, 6:R2.
69. Bixel M, Shimomura Y, Hutson S, Hamprecht B: Distribution of key
enzymes of branched-chain amino acid metabolism in glial
and neuronal cells in culture.  J Histochem Cytochem 2001,
49:407-418.
70. Kanamori K, Ross BD, Kondrat RW: Rate of glutamate synthesis
from leucine in rat brain measured in vivo by 15N NMR.  J
Neurochem 1998, 70:1304-1315.
71. Fountoulakis M, Juranville J, Dierssen M, Lubec G: Proteomic anal-
ysis of the fetal brain.  Proteomics 2002, 2:1547-1576.
72. Papes F, Surpili MJ, Langone F, Trigo JR, Arruda P: The essential
amino acid lysine acts as precursor of glutamate in the mam-
malian central nervous system.  FEBS Lett 2001, 488:34-38.
73. Acworth IN, During MJ, Wurtman RJ: Tyrosine: effects on cate-
cholamine release.  Brain Res Bull 1988, 21:473-477.
74. Siegel J, Agranoff BW, Albers RW, Molinof PB: Basic neurochemistry:
molecular, cellular, and medical aspects Raven Press; 1993. 
75. Bronk JR: Human metabolism: functional diversity and integration Addi-
son-Wesley/Longman; 1999. 
76. Elsworth JD, Roth RH: Dopamine synthesis, uptake, metabo-
lism, and receptors: relevance to gene therapy of parkinson's
disease.  Exp Neurol 1997, 144:4-9.
77. Webster RA: Dopamine (da).  In Neurotransmitters, Drugs And Brain
Function John Wiley and Sons; 2001:137-161. 
78. Inazu M, Takeda H, Matsumiya T: Functional expression of the
norepinephrine transporter in cultured rat astrocytes.  J Neu-
rochem 2003, 84:136-144.
79. Diksic M, Young SN: Study of the brain serotonergic system
with labeled alpha-methyl-l-tryptophan.  J Neurochem 2001,
78:1185-1200.
80. Ma K, Langenbach R, Rapoport SI, Basselin M: Altered brain lipid
composition in cyclooxygenase-2 knockout mouse.  J Lipid Res
2007, 48:848-854.
81. Pfrieger FW: Outsourcing in the brain: do neurons depend on
cholesterol delivery by astrocytes?  Bioessays 2003, 25:72-78.
82. Jurevics H, Morell P: Cholesterol for synthesis of myelin is made
locally, not imported into brain.  J Neurochem 1995, 64:895-901.
83. Björkhem I, Meaney S: Brain cholesterol: long secret life behind
a barrier.  Arterioscler Thromb Vasc Biol 2004, 24:806-815.
84. Pfrieger FW: Cholesterol homeostasis and function in neurons
of the central nervous system.  Cell Mol Life Sci 2003,
60:1158-1171.
85. Ando S, Tanaka Y: Mass spectrometric studies on brain metab-
olism, using stable isotopes.  Mass Spectrom Rev 2005,
24:865-886.
86. Moore SA: Polyunsaturated fatty acid synthesis and release by
brain-derived cells in vitro.  J Mol Neurosci 2001, 16:195-200. dis-
cussion 215–21.
87. Moore SA, Yoder E, Murphy S, Dutton GR, Spector AA: Astrocytes,
not neurons, produce docosahexaenoic acid (22:6 omega-3)
and arachidonic acid (20:4 omega-6).  J Neurochem 1991,
56:518-524.
88. Ulmann L, Mimouni V, Roux S, Porsolt R, Poisson JP: Brain and hip-
pocampus fatty acid composition in phospholipid classes of
aged-relative cognitive deficit rats.  Prostaglandins Leukot Essent
Fatty Acids 2001, 64:189-195.
89. Norton WT, Abe T, Poduslo SE, DeVries GH: The lipid composi-
tion of isolated brain cells and axons.  J Neurosci Res 1975,
1:57-75.
90. Barceló-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ:
Brain neutral lipids mass is increased in alpha-synuclein
gene-ablated mice.  J Neurochem 2007, 101:132-141.
91. Svennerholm L: Distribution and fatty acid composition of
phosphoglycerides in normal human brain.  J Lipid Res 1968,
9:570-579.
92. Farooqui AA, Horrocks LA, Farooqui T: Glycerophospholipids in
brain: their metabolism, incorporation into membranes,
functions, and involvement in neurological disorders.  Chem
Phys Lipids 2000, 106:1-29.
93. Nguyen NHT, Bråthe A, Hassel B: Neuronal uptake and metab-
olism of glycerol and the neuronal expression of mitochon-
drial glycerol-3-phosphate dehydrogenase.  J Neurochem 2003,
85:831-842.Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
Page 17 of 18
(page number not for citation purposes)
94. Bender AS, Reichelt W, Norenberg MD: Characterization of cys-
tine uptake in cultured astrocytes.  Neurochem Int 2000,
37:269-276.
95. Heales SJR, Lam AAJ, Duncan AJ, Land JM: Neurodegeneration or
neuroprotection: the pivotal role of astrocytes.  Neurochem
Res 2004, 29:513-519.
96. Gruetter R: Glycogen: the forgotten cerebral energy store.  J
Neurosci Res 2003, 74:179-183.
97. Hertz L, Peng L, Dienel GA: Energy metabolism in astrocytes:
high rate of oxidative metabolism and spatiotemporal
dependence on glycolysis/glycogenolysis.  J Cereb Blood Flow
Metab 2007, 27:219-249.
98. Oz G, Seaquist ER, Kumar A, Criego AB, Benedict LE, Rao JP, Henry
P, Van De Moortele P, Gruetter R: Human brain glycogen con-
tent and metabolism: implications on its role in brain energy
metabolism.  Am J Physiol Endocrinol Metab 2007, 292:E946-51.
99. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG: Energy on
demand.  Science 1999, 283:496-497.
100. Oz G, Berkich DA, Henry P, Xu Y, LaNoue K, Hutson SM, Gruetter
R: Neuroglial metabolism in the awake rat brain: co2 fixation
increases with brain activity.  J Neurosci 2004, 24:11273-11279.
101. Abe T, Takahashi S, Suzuki N: Oxidative metabolism in cultured
rat astroglia: effects of reducing the glucose concentration in
the culture medium and of d-aspartate or potassium stimu-
lation.  J Cereb Blood Flow Metab 2006, 26:153-160.
102. Edmond J, Robbins RA, Bergstrom JD, Cole RA, de Vellis J: Capacity
for substrate utilization in oxidative metabolism by neurons,
astrocytes, and oligodendrocytes from developing brain in
primary culture.  J Neurosci Res 1987, 18:551-561.
103. Aureli T, Di Cocco ME, Calvani M, Conti F: The entry of [1-
13c]glucose into biochemical pathways reveals a complex
compartmentation and metabolite trafficking between glia
and neurons: a study by 13C-NMR spectroscopy.  Brain Res
1997, 765:218-227.
104. Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, Mason GF,
Petroff OA, Shulman GI, Shulman RG, Rothman DL: Determination
of the rate of the glutamate/glutamine cycle in the human
brain by in vivo 13C NMR.  Proc Natl Acad Sci USA 1999,
96:8235-8240.
105. Lubow JM, Piñón IG, Avogaro A, Cobelli C, Treeson DM, Mandeville
KA, Toffolo G, Boyle PJ: Brain oxygen utilization is unchanged
by hypoglycemia in normal humans: lactate, alanine, and leu-
cine uptake are not sufficient to offset energy deficit.  Am J
Physiol Endocrinol Metab 2006, 290:E149-E153.
106. Madsen PL, Cruz NF, Sokoloff L, Dienel GA: Cerebral oxygen/glu-
cose ratio is low during sensory stimulation and rises above
normal during recovery: excess glucose consumption during
stimulation is not accounted for by lactate efflux from or
accumulation in brain tissue.  J Cereb Blood Flow Metab 1999,
19:393-400.
107. Nybo L, Nielsen B, Blomstrand E, Moller K, Secher N: Neurohu-
moral responses during prolonged exercise in humans.  J Appl
Physiol 2003, 95:1125-1131.
108. Wahren J, Ekberg K, Fernqvist-Forbes E, Nair S: Brain substrate
utilisation during acute hypoglycaemia.  Diabetologia 1999,
42:812-818.
109. Gruetter R: In vivo 13C NMR studies of compartmentalized
cerebral carbohydrate metabolism.  Neurochem Int 2002,
41:143-154.
110. Berl S, Clarke DD: The metabolic compartmentation concept.
In Glutamine, Glutamate And GABA In The Central Nervous System Edited
by: Hertz L, Kvamme E, McGeer EG, Schousboe A, Alan R. Liss, Inc;
1983:205-217. 
111. Schousboe A, Westergaard N, Sonnewald U, Petersen SB, Huang R,
Peng L, Hertz L: Glutamate and glutamine metabolism and
compartmentation in astrocytes.  Dev Neurosci 1993,
15:359-366.
112. Daikhin Y, Yudkoff M: Compartmentation of brain glutamate
metabolism in neurons and glia.  J Nutr 2000, 130:1026S-31S.
113. Holzhutter H: The generalized flux-minimization method and
its application to metabolic networks affected by enzyme
deficiencies.  Biosystems 2006, 83:98-107.
114. Segre D, Vitkup D, Church GM: Analysis of optimality in natural
and perturbed metabolic networks.  Proc Natl Acad Sci USA 2002,
99:15112-15117.
115. Chateil J, Biran M, Thiaudiere E, Canioni P, Merle M: Metabolism of
[1-(13)c)glucose and [2-(13)c]acetate in the hypoxic rat
brain.  Neurochem Int 2001, 38:399-407.
116. Marrif H, Juurlink BH: Astrocytes respond to hypoxia by
increasing glycolytic capacity.  J Neurosci Res 1999, 57:255-260.
117. Cheeseman AJ, Clark JB: Influence of the malate-aspartate shut-
tle on oxidative metabolism in synaptosomes.  J Neurochem
1988, 50:1559-1565.
118. Drewes LR, Gilboe DD: Glycolysis and the permeation of glu-
cose and lactate in the isolated, perfused dog brain during
anoxia and postanoxic recovery.  J Biol Chem 1973,
248:2489-2496.
119. Harik SI, Behmand RA, LaManna JC: Hypoxia increases glucose
transport at blood-brain barrier in rats.  J Appl Physiol 1994,
77:896-901.
120. Allen NJ, Káradóttir R, Attwell D: A preferential role for glycol-
ysis in preventing the anoxic depolarization of rat hippocam-
pal area ca1 pyramidal cells.  J Neurosci 2005, 25:848-859.
121. Hori O, Matsumoto M, Maeda Y, Ueda H, Ohtsuki T, Stern DM,
Kinoshita T, Ogawa S, Kamada T: Metabolic and biosynthetic
alterations in cultured astrocytes exposed to hypoxia/reoxy-
genation.  J Neurochem 1994, 62:1489-1495.
122. Martinez AD, Saez JC: Regulation of astrocyte gap junctions by
hypoxia-reoxygenation.  Brain Res Brain Res Rev 2000, 32:250-258.
123. Leo GC, Driscoll BF, Shank RP, Kaufman E: Analysis of [1-13c]d-
glucose metabolism in cultured astrocytes and neurons
using nuclear magnetic resonance spectroscopy.  Dev Neurosci
1993, 15:282-288.
124. Pellerin L, Magistretti PJ: Glutamate uptake into astrocytes
stimulates aerobic glycolysis: a mechanism coupling neuro-
nal activity to glucose utilization.  Proc Natl Acad Sci USA 1994,
91:10625-10629.
125. Cakir T, Tacer CS, Ulgen KO: Metabolic pathway analysis of
enzyme-deficient human red blood cells.  Biosystems 2004,
78:49-67.
126. Lee K, Berthiaume F, Stephanopoulos GN, Yarmush DM, Yarmush
ML: Metabolic flux analysis of postburn hepatic hypermetab-
olism.  Metab Eng 2000, 2:312-327.
127. Nadeau I, Sabatie J, Koehl M, Perrier M, Kamen A: Human 293 cell
metabolism in low glutamine-supplied culture: interpreta-
tion of metabolic changes through metabolic flux analysis.
Metab Eng 2000, 2:277-292.
128. Sheikh K, Forster J, Nielsen LK: Modeling hybridoma cell metab-
olism using a generic genome-scale metabolic model of mus
musculus.  Biotechnol Prog 2005, 21:112-121.
129. Raman K, Rajagopalan P, Chandra N: Flux balance analysis of
mycolic acid pathway: targets for anti-tubercular drugs.  PLoS
Comput Biol 2005, 1:e46.
130. Thiele I, Price ND, Vo TD, Palsson BO: Candidate metabolic net-
work states in human mitochondria. impact of diabetes,
ischemia, and diet.  J Biol Chem 2005, 280:11683-11695.
131. Covert MW, Palsson BO: Transcriptional regulation in con-
straints-based metabolic models of escherichia coli.  J Biol
Chem 2002, 277:28058-28064.
132. Cox SJ, Shalel Levanon S, Bennett GN, San K: Genetically con-
strained metabolic flux analysis.  Metab Eng 2005, 7:445-456.
133. Fell DA, Small JR: Fat synthesis in adipose tissue. an examina-
tion of stoichiometric constraints.  Biochem J 1986, 238:781-786.
134. Lee S, Phalakornkule C, Domach MM, Grossmann IE: Recursive
milp model for finding all the alternate optima in lp models
for metabolic networks.  Comp Chem Eng 2000, 2:711-716.
135. Mahadevan R, Schilling CH: The effects of alternate optimal
solutions in constraint-based genome-scale metabolic mod-
els.  Metab Eng 2003, 5:264-276.
136. Bonarius HPJ, Hatzimanikatis V, Meesters KPH, de Gooijer CD,
Schmid G, Tramper J: Metabolic flux analysis of hybridoma cells
in different culture media using mass balances.  Biotechnol Bio-
eng 1996, 50:299-318.
137. Holzhutter H: The principle of flux minimization and its appli-
cation to estimate stationary fluxes in metabolic networks.
Eur J Biochem 2004, 271:2905-2922.
138. Beasley JE, Planes FJ: Recovering metabolic pathways via opti-
mization.  Bioinformatics 2007, 23:92-98.
139. COIN-OR Linear Program Solver   [http://www.coin-or.org/Clp/
index.html]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Theoretical Biology and Medical Modelling 2007, 4:48 http://www.tbiomed.com/content/4/1/48
Page 18 of 18
(page number not for citation purposes)
140. Mexclp:Matlab Interface To CLP   [http://control.ee.ethz.ch/
~joloef/clp.php]
141. Bradford HF: Chemical neurobiology: an introduction to neurochemistry
W. H. Freeman; 1986. 
142. Dienel GA, Cruz NF: Neighborly interactions of metabolically-
activated astrocytes in vivo.  Neurochem Int 2003, 43:339-354.
143. Dienel GA, Cruz NF: Nutrition during brain activation: does
cell-to-cell lactate shuttling contribute significantly to sweet
and sour food for thought?  Neurochem Int 2004, 45:321-351.
144. Nehlig A, Wittendorp-Rechenmann E, Lam CD: Selective uptake
of [14c]2-deoxyglucose by neurons and astrocytes: high-res-
olution microautoradiographic imaging by cellular 14c-tra-
jectography combined with immunohistochemistry.  J Cereb
Blood Flow Metab 2004, 24:1004-1014.
145. Louis Sokoloff: Energy metabolism in neural tissues in vivo at
rest and in functionally altered states.  In Brain Energetics And
Neuronal Activity Edited by: RG Shulman DR. Wiley; 2004:11-30. 
146. Cooper AJ, McDonald JM, Gelbard AS, Gledhill RF, Duffy TE: The
metabolic fate of 13n-labeled ammonia in rat brain.  J Biol
Chem 1979, 254:4982-4992.
147. Ott P, Larsen FS: Blood-brain barrier permeability to ammonia
in liver failure: a critical reappraisal.  Neurochem Int 2004,
44:185-198.
148. Sibson NR, Dhankhar A, Mason GF, Behar KL, Rothman DL, Shulman
RG: In vivo 13C NMR measurements of cerebral glutamine
synthesis as evidence for glutamate-glutamine cycling.  Proc
Natl Acad Sci USA 1997, 94:2699-2704.
149. Lockwood AH, Yap EW, Wong WH: Cerebral ammonia metab-
olism in patients with severe liver disease and minimal
hepatic encephalopathy.  J Cereb Blood Flow Metab 1991,
11:337-341.
150. Wang XF, Cynader MS: Astrocytes provide cysteine to neurons
by releasing glutathione.  J Neurochem 2000, 74:1434-1442.
151. Wiesinger H, Hamprecht B, Dringen R: Metabolic pathways for
glucose in astrocytes.  Glia 1997, 21:22-34.
152. Ben-Yoseph O, Camp DM, Robinson TE, Ross BD: Dynamic meas-
urements of cerebral pentose phosphate pathway activity in
vivo using [1,6-13c2,6,6-2h2]glucose and microdialysis.  J Neu-
rochem 1995, 64:1336-1342.
153. Hostetler KY, Landau BR: Estimation of the pentose cycle con-
tribution to glucose metabolism in tissue in vivo.  Biochemistry
1967, 6:2961-2964.
154. Patel AB, de Graaf RA, Mason GF, Rothman DL, Shulman RG, Behar
KL:  The contribution of GABA to glutamate/glutamine
cycling and energy metabolism in the rat cortex in vivo.  Proc
Natl Acad Sci USA 2005, 102:5588-5593.
155. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman
RG:  Stoichiometric coupling of brain glucose metabolism
and glutamatergic neuronal activity.  Proc Natl Acad Sci USA
1998, 95:316-321.
156. Hyder F, Patel AB, Gjedde A, Rothman DL, Behar KL, Shulman RG:
Neuronal-glial glucose oxidation and glutamatergic-gabaer-
gic function.  J Cereb Blood Flow Metab 2006, 26:865-877.